MedTrace Logo

The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation

NCT01065376 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2011-07-21

No results posted yet for this study

Summary

The dopamine agonist cabergoline inhibits phosphorylation of the vascular endothelial growth factor receptor-2(VEGFR-2), which prevent vascular endothelial growth factor (VEGF) overexpression and reduce the severity of Ovarian hyperstimulation syndrome. However, VEGF plays an important role in the growth and maintenance of ovarian follicle and developing embryo by mediating angiogenesis.This study was designed to analyze whether the timing cabergoline administration on the day of human chorionic gonadotropin (hCG) injection or after oocytes retrieved affects the oocyte maturation and outcome of assisted reproduction treatment.

Conditions

  • In Vitro Fertilization

Interventions

PROCEDURE

the timing cabergoline administration

received 0.5 mg oral cabergoline per day for 8 days on the day of hCG

PROCEDURE

the timing cabergoline administration

received 0.5 mg oral cabergoline per day for 8 days on the day after oocyte retrieval

Sponsors & Collaborators

  • Shin Kong Wu Ho-Su Memorial Hospital

    lead OTHER

Principal Investigators

  • Jiann-Loung Hwang, MD · Shin Kong Wu Ho-Su Memorial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-06-30
Completion
2011-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01065376 on ClinicalTrials.gov